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Abstract 
Purpose: To investigate the implication of eosinophilia in atopic dermatitis (AD).  
Methods: A total of 139 AD patients from The First Affiliated Hospital of Guangxi University of Chinese 
Medicine between February 2013 and May 2015, were involved in this study. Scoring atopic dermatitis 
(SCORAD) index was used to evaluate the skin lesions. The levels of IL-4, IL-5, IL-13, IL-17, INF-
gamma, IP-10, eotaxin and Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES), 
were determined with commercial enzyme-linked immunosorbent assay (ELISA) kits. Eosinophil counts 
were carried out by granulocyte count method. Correlation between SCORAD scores and levels of 
cytokines was analyzed using the Spearman correlation method. 
Results: SCORAD scores significantly increased in the eosinophil-positive group when compared to 
eosinophil-negative group (p < 0.05). Eosinophil counts correlated with SCORAD scores in the 
eosinophil-positive group (p < 0.05). INF-γ, IP-10 and RANTES levels were significantly higher in the 
eosinophil-positive group than in eosinophil- negative group, while IL-5, eotaxin and IL-17 levels 
significantly decreased in eosinophil-positive group (p < 0.05). In the eosinophil-positive group, IL-5, 
eotaxin and IL-17 levels positively correlated with SCORAD scores.  
Conclusion: Eosinophilia triggers lL-5, eotaxin and IL-17 changes and acts as a prognostic biomarker 
for atopic dermatitis. These findings may give further insights into the pathogenesis of AD. 
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Atopic dermatitis (AD) is a common chronic 
inflammatory and relapsing skin disease, which 
is always associated with food allergies and 
asthma [1]. Previous studies showed that 
industrialization and urbanization influence the 
rates of atopic disease [2,3]. Recent studies 
revealed that the prevalence of AD decreases 
from in central and rural areas of Shanghai, 
China [4]. The International Study of Asthma and 
Allergies in Childhood (ISAAC) showed that the 
incidence and prevalence of AD are on the 
increase all over the world, especially in the 
developing countries [5]. AD places a heavy 
economic burden on the society and is a source 
of huge financial costs to health systems [6]. 
 
Many studies have been reported that AD may 
be induced when the skin is stimulated by 
allergens [7,8]. Recent studies also reported that 
some of environmental allergens could produce 
eczematous reactions on the skin [7,8]. However 
the pathogenesis of AD and its immune 
responses are still not clearly understood. It has 
been shown that chronic immune activation 
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contributes to the pathophysiology of this 
common skin disease, and that eosinophils are 
frequently observed in AD patients [8].  
 
Elevated blood eosinophil count is an important 
characteristic of AD patients [9]. However, the 
reasons for the elevation in blood eosinophil 
count have not been fully elucidated [10]. It has 
been speculated that the eosinophils may play 
protective roles in AD [9,10]. Previous studies 
have demonstrated that eosinophils are activated 
pro-inflammatory cells which could cause some 
of the allergic inflammation symptoms. 
 
Recent studies on activities of eosinophils 
revealed that they contain potent toxic proteins 
with the potential to mediate tissue damage [8-
10]. Furthermore, immuno-fluorescent 
localization of eosinophil granule proteins has 
shown that the toxic granule proteins were 
deposited in tissues when the eosinophils 
become disrupted [10]. The deposition of granule 
proteins in several diseases is vastly out of 
proportion with the number of identifiable cells 
[9]. Specifically, the deposition of eosinophil 
granule proteins outside of eosinophils has been 
observed in lichenified eczematous disorders 
with elevated serum levels of immunoglobulin E; 
in urticarial and angioedematous disorders, and 
in bullous diseases [10].  
The present study was carried out to investigate 
the prognostic biomarker potential of eosinophils 





The survey was performed at the First Affiliated 
Hospital of Guangxi University of Chinese 
Medicine, China. A total of 139 children aged 2 to 
12 years, who were clinically diagnosed with AD, 
were recruited. This study was approved by the 
Ethical Committee of The First Affiliated Hospital 
of Guangxi University of Chinese Medicine, 
Nanning, China (approval no. [2013]-K002). 
Informed consents were obtained from all of the 
participants. All of the patients have been 
approved this study. The duration of disease in 
every patient was more than six months, and the 
remission was less than 3 months in a year 
(Figure 1). In accordance with the Guidelines of 
the World Medical Association Declaration of 
Helsinki [11], patients were treated with 
loratadine granules per os and desonide for 
external use. 
 
All the AD patients underwent 2 year-long follow-
up and 3 months of regular visits. Blood samples 
were collected for determination of eosinophil 
counts and related cytokines, including IL-4, IL-5, 
IL-13, IL-17, INF-gamma, IP-10, eosinophil 
chemotactic factor eotaxin and RANTES. The 
study subjects were grouped into eosinophil-
positive group (58 cases) and eosinophil-
negative group (61 cases). 
 
 
Figure 1: Patients clinically diagnosed with AD illustrating different syndromes. A. Dermatitis at oral lips. B. 
Dermatitis at nape. C. Dermatitis at hand. D. Dermatitis at leg 
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ELISA and eosinophil counts assay 
 
Blood levels of IL-4, IL-5, IL-13, IL-17, INF-
gamma, IP-10, eotaxin and RANTES were 
determined using ELISA commercial kits. 
Eosinophil counts were carried out using 
granulocyte count method. 
 
European AD score (SCORAD) 
 
Scoring atopic dermatitis index (SCORAD) was 
used as AD standard to assess the extent of skin 
lesions (A), the severity of skin lesions (B) and 
pruritus and sleep (C). The score guide was as 
follows:  
 
A (1) for adults: 9 % for head, neck and arm; 
13.5 % for each side of trunk, and 22.5 % for the 
lower extremities. A (2) for children under 14 
years of age: 9% for head and neck, and 18% for 
arm, trunk and lower limbs.  
 
B represented scores (0 - 3) in respect skin 
lesions such as erythema, papules, edema, skin 
exfoliation, cracking, chapping and exudation, 
scab, moss or dry skin. C, which represented 
scores (0 - 3) for pruritis and extent of effect on 
sleep, was divided into four grades: severe (3 
points), moderate (2 points), mild (1 point) and nil 




Data analyses were performed using SPSS 20.0 
software. Student’s t test was used to evaluate 
significant differences between groups. P < 0.05 
was considered statistically significant. 
Correlation between SCORAD scores and levels 





SCORAD scores  
 
The results indicated that eosinophil counts in 
the eosinophil-positive group were significantly 
higher when compared to corresponding values 
in the eosinophil-negative group, irrespective of 
AD duration (p < 0.05, Table 1). SCORAD scores 
were also significantly higher in the eosinophil-
positive group than in the eosinophil-negative 
group in "Half year", "One year", "One-and-half 
year" and "Two years" categories (p < 0.05, 
Table 1). However, eosinophil counts and 
SCORAD scores were significantly lowered from 
"Half year" to "Two years" in the eosinophil-
negative group (p < 0.05, Table 1). SCORAD 
scores were correlated with eosinophil counts in 
both groups. The results also revealed that 
eosinophil counts were positively correlated with 
SCORAD scores in the eosinophil-positive group 
(Figure 2, p < 0.05). 
 
 
Figure 2: Correlation analysis between SCORAD 
scores and the eosinophils counts in eosinophils 
positive group (A) and negative group (B) 
 
INF-γ, IP-10 and RANTES levels  
 
The results showed that INF-γ, IP-10 and 
RANTES levels were significantly higher in "One 
year" compared to "Half year";  and in "One-and-
half year" AD when compared to "One year" AD 
(post-diagnosis) in the eosinophil-positive group 
(p < 0.05, Table 2). For the INF-γ and RANTES,
 
Table 1: Eosinophil counts and SCORAD scores in eosinophils positive and negative groups at half year, one 
year, one and half year and two years after diagnosis of AD 
 
Time Eosinophils positive group Eosinophils negative group 
  Counts (109／L) SCORAD Counts (109／L) SCORAD 
Half year 0.97±0.28 6.28±1.77 1.32±0.29 10.05±3.12 
One year 1.05±0.33 9.41±2.85 1.06±0.25 6.91±1.83 
One and half year 1.53±0.41 14.03±4.26 1.06±0.25 9.24±3.07 
Two year 1.46±0.37 15.74±5.14 0.47±0.08 8.32±2.75 
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Table 2: Observation for the INF-γ, IP-10 and RANTES expression in the eosinophils positive group at half year, 
one year, one and half year and two years after diagnosis of AD 
 
Time INF-γ (pg/ml) IP-10 (pg/ml) RANTES (pg/mL) 
Half-year 29.563±3.815 70.324±43.501 54.813±12.068 
One year 47.06±5.493 116.550±58.947 93.054±30.245 
One and half year 324.612±76.524 209.548±97.513 912.356±105.436 
Two years 291.64±64.307 241.538±122.095 876.590±94.021 
 
Table 3: Examination of the IL-5, extaxin and IL-17 expression in the eosinophils positive group at half year, one 
year, one and half year and two years after diagnosis of AD 
 
Time IL-5 (pg/mL) Eotaxin (pg/mL) IL-17 (pg/mL) 
Half year 84.786±10.257 54.910±20.136 92.744±17.391 
One year 75.042±9.035 34.756±15.382 30.927±3.895 
One and half year 66.793±8.578 49.651±18.523 75.782±8.653 
Two year 36.245±5.749 41.207±16.113 58.237±6.507 
 
Figure 3: Correlation analysis between SOCRAD 
scores and the INF-γ (A), IP-10 (B) and RANTES (C) 
levels in the ensinophils positive group 
 
the levels were significantly lower in the "Two 
years" compared to "One-and-half year" AD 
post-diagnosis (Table 2). 
 
Results from analysis of the correlation between 
SCORAD scores and INF-γ, IP-10 and RANTES 
levels indicated that there were no significant 
correlations between INF-γ and SCORAD scores 
(Figure 3A, p > 0.05); or between IP-10 and 
SCORAD scores (Figure 3B,) or between 
RANTES and SCORAD scores (Plate 3C, p > 
0.05). 
 
IL-5, eotaxin and IL-17 levels  
 
The results obtained showed that the levels of IL-
5, eotaxin and IL-17 were significantly lower in 
"One year", "One-and-half year" and "Two-year" 
post AD diagnosis categories when compared to 
the "Half year" post-diagnosis group (Table 3, p 
< 0.05). 
 
Results from cytokine assays showed that IL-5, 
extaxin and IL-17 levels were positively 
correlated with SCORAD scores (Figure 4, 
p<0.05). 
 
Furthermore, IL-4 and IL-13 levels were 
significantly lower in "One year", "One-and-half 
year" and "Two-year" when compared to "Half 
year" post-diagnosis (data not shown). However, 
IL-4 and IL-13 were not correlated with SCORAD 
scores in the eosinophil-positive patients (data 
not shown). 
 
negative groups. The results indicated that 
SCORAD scores were significantly increased in 
the eosinophil-positive group. Furthermore, 
eosinophil counts correlated positively with 
SCORAD scores in eosinophil-positive group. 
These results suggest that eosinophil levels were 
associated with the SCORAD scores in the 
eosinophil-positive patients, indicating that 
eosinophil levels could reflect the level of skin 
injury in AD patients. 
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F
igure 4: Correlation analysis between SOCRAD 
scores and the IL-5 (A), eotaxin (B) and IL-17 (C) 
levels in the eosinophils positive group 
 
Although INF-γ, IP-10 and RANTES levels were 
significantly increased in the eosinophil-positive 
group, no correlations were established between 
levels of INF-γ, IP-10 and RANTES, and 
SCORAD scores in the eosinophil-positive 
patients. These results suggest that the INF-γ, 
IP-10 and RANTES cannot be used to evaluate 
the severity of AD. However, IL-5, eotaxin and IL-
17 levels were correlated with SCORAD scores 
in eosinophil-positive patients, indicating that the 
IL-5, eotaxin and IL-17 can be used to evaluate 
the severity of AD. Studies by Valirlis et al [17] 
also found that some of the cytokine were 
associated with SCORAD scores in acute AD 
patients. However, not much was known about 
the involvement of INF-γ, IP-10, RANTES, IL-5, 
eotaxin and IL-17. The present study is the first 
report to demonstrate that cytokines, IL-5, 
eotaxin and IL-17 levels correlated with 
SCORAN scores and skin injury in eosinophil-
positive patients. However, IL-4 and IL-13 were 





AD  is  a  chronic,  relapsing  and  highly  pruritic 
dermatitis which always develops in early 
childhood. It has a characteristic age-dependent 
distribution. About 10 to 20 % children suffer 
from AD in the developing countries [12]. AD is 
characterized by sino-pulmonary infections, 
dermatitis, cutaneous viral infections, altered 
eosinophil levels, elevated serum IgE, squamous 
cell carcinomas, and a high incidence of food 
allergies [12-14]. Aarkawa et al reported that 
different cytokines are present in the peripheral 
blood mononuclear cells of patients with atopic 
dermatitis [15]. Therefore, in this study, we 
investigated the prognostic value of eosinophil 
and related cytokines in atopic dermatitis. 
 
Previous studies reported that the peripheral 
blood eosinophil could act as a diagnostic 
parameter in differentiating allergic AD from non-
allergic AD [16]. The present study also showed 
that eosinophil counts in AD patients changed 
significantly, which is consistent with the previous 
study [16]. Furthermore, the AD patients were 




The results obtained in this study strongly 
suggest that eosinophils act as prognostic 
biomarkers for AD by triggering changes in lL-5, 
eotaxin and IL-17. The findings of this study may 
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